Infectious Disease and Microbiology: Histoplasmosis




Histoplasmosis is an inhalation-acquired fungal infection primarily affecting the lungs and caused by the dimorphic fungus Histoplasma capsulatum. It is an endemic mycosis, meaning it occurs in specific geographic regions, and infection typically follows inhalation of fungal spores from contaminated environments such as soil enriched with bird or bat droppings.


Epidemiologically, histoplasmosis is most common in areas such as the Ohio and Mississippi River valleys in the United States, with hundreds of thousands of infections occurring annually. Although both sexes are equally exposed, disseminated disease is more common in males. Individuals at highest risk include infants, older adults, and especially immunocompromised patients, such as those with HIV/AIDS, malignancies, organ transplants, or those receiving immunosuppressive therapies.


The pathophysiology begins when microconidia (infectious spores) are inhaled into the lungs. Inside the host, the organism converts from its mold form to a yeast form and multiplies within macrophages. This intracellular survival allows the fungus to spread through the reticuloendothelial system. While most infections remain localized and asymptomatic, impaired immunity can lead to widespread dissemination affecting multiple organs.


Clinically, histoplasmosis presents in several forms. Acute pulmonary histoplasmosis is often asymptomatic or presents as a mild flu-like illness with fever, cough, chest pain, and malaise. Chronic pulmonary histoplasmosis, typically seen in older individuals with underlying lung disease, resembles tuberculosis with symptoms such as chronic cough, weight loss, night sweats, and hemoptysis. Disseminated histoplasmosis is the most severe form, particularly in immunocompromised patients, and may involve fever, hepatosplenomegaly, skin lesions, adrenal insufficiency, or even central nervous system involvement.


Physical examination findings vary depending on the form of disease but may include enlarged liver and spleen, skin eruptions, or mucosal ulcers in disseminated disease. Pulmonary findings such as crackles or signs of consolidation may also be present. In some cases, complications such as mediastinal fibrosis or pericarditis can occur due to lymph node involvement.


Diagnosis is established through a combination of laboratory and imaging studies. Detection of Histoplasma antigen in urine or serum is highly sensitive, especially in disseminated disease. Fungal cultures can confirm the diagnosis but may take several weeks. Serologic tests, PCR, and histopathological examination of tissue samples showing granulomas with yeast forms are also useful. Imaging studies, such as chest X-rays or CT scans, may reveal pulmonary infiltrates, nodules, calcifications, or lymphadenopathy.


Treatment depends on disease severity. Mild acute pulmonary histoplasmosis often requires no treatment and resolves spontaneously. More severe or persistent cases are treated with antifungal agents such as itraconazole. Severe or disseminated disease requires initial therapy with amphotericin B followed by prolonged itraconazole therapy. Immunocompromised patients may require long-term suppressive therapy to prevent relapse.


The prognosis of histoplasmosis is generally good in mild cases but can be life-threatening in disseminated disease, particularly in immunosuppressed individuals. Complications include chronic lung damage, adrenal insufficiency, mediastinal fibrosis, and, in severe cases, respiratory failure or death. Early recognition and appropriate antifungal therapy are critical in improving outcomes.

​

Infectious Disease and Microbiology: Herpes Zoster (Shingles)




Herpes zoster, commonly known as shingles, is a localized skin and nerve infection caused by reactivation of the Varicella zoster virus, the same virus responsible for chickenpox. After a primary infection, the virus remains dormant in sensory nerve ganglia for years. Reactivation later in life leads to herpes zoster, typically presenting as a painful, vesicular rash confined to a specific dermatome.


Epidemiologically, herpes zoster occurs worldwide and affects approximately 20% of individuals during their lifetime. The incidence increases significantly with age, particularly in those over 50 years. Nearly 90% of adults have evidence of prior VZV infection, placing them at risk for reactivation. Immunocompromised individuals—such as those with HIV infection, malignancies, or those receiving immunosuppressive therapy—are at particularly high risk and may develop more severe or disseminated disease.


The pathophysiology involves reactivation of latent virus within dorsal root or cranial nerve ganglia. The virus travels along sensory nerves to the skin, producing inflammation and the characteristic painful rash. The exact triggers for reactivation are not fully understood but are strongly associated with declining cell-mediated immunity, especially in aging or immunosuppressed individuals.


Clinically, patients typically present with localized pain, burning, or tingling in a dermatomal distribution, often preceding the rash by a few days. This is followed by the appearance of grouped vesicles on an erythematous base, usually confined to one side of the body. The thoracic and lumbar dermatomes are most commonly affected. Involvement of the trigeminal nerve may lead to ocular complications (herpes zoster ophthalmicus), while involvement of the geniculate ganglion can result in Ramsay Hunt syndrome, characterized by ear lesions and facial paralysis.


Diagnosis is primarily clinical, based on the typical unilateral dermatomal rash and associated pain. Laboratory tests such as PCR or serology can confirm the diagnosis but are rarely necessary in routine cases. Imaging or lumbar puncture may be required if central nervous system involvement is suspected.


Treatment focuses on antiviral therapy and pain management. First-line therapy includes oral acyclovir, while alternatives such as valacyclovir or famciclovir offer improved dosing convenience. In severe cases or immunocompromised patients, intravenous antivirals may be required. Adjunctive therapies, including analgesics and sometimes corticosteroids, may help reduce acute symptoms, although steroids do not prevent long-term complications.


The prognosis is generally good in immunocompetent individuals, but complications are not uncommon. The most significant is postherpetic neuralgia, a chronic pain condition that can persist long after the rash resolves, particularly in older adults. Other complications include secondary bacterial infection, ocular damage potentially leading to blindness, and, in severe cases, systemic involvement such as pneumonitis, hepatitis, or central nervous system disease.


Prevention includes vaccination against VZV, which reduces both the incidence of herpes zoster and the risk of postherpetic neuralgia. In high-risk individuals, prophylactic antivirals or immunoglobulin may be used following exposure.

​

​Emergency and Acute Medicine – Wolff–Parkinson–White (WPW) Syndrome


Wolff–Parkinson–White syndrome (WPW) is a cardiac conduction disorder caused by the presence of an accessory pathway (Kent bundle) that bypasses the atrioventricular (AV) node, allowing premature ventricular activation (pre-excitation). On ECG, the WPW pattern is characterized by a short PR interval (<0.12 sec), a delta (Δ) wave representing early ventricular depolarization, and a widened QRS complex (>0.10 sec). While the ECG pattern alone is termed WPW pattern, the diagnosis of WPW syndrome requires both these findings and associated tachydysrhythmias.


Accessory pathways occur in approximately 0.1–0.3% of the population and are most commonly located along the left lateral free wall, followed by the posteroseptal region. Conduction through these pathways may occur in antegrade, retrograde, or bidirectional fashion. The most common arrhythmia associated with WPW is orthodromic atrioventricular re-entrant tachycardia (AVRT) (≈70%), where impulses travel down the AV node and return via the accessory pathway, producing a narrow complex tachycardia. Less commonly, antidromic AVRT (≈30%) occurs, with conduction down the accessory pathway and back through the AV node, resulting in a wide complex tachycardia. WPW can also precipitate atrial fibrillation with rapid ventricular response, which carries a risk of degeneration into ventricular fibrillation and sudden death.


Patients may be asymptomatic or present with palpitations, chest pain, dyspnea, dizziness, diaphoresis, or syncope. Physical findings depend on the rhythm and hemodynamic status, ranging from stable tachycardia to signs of instability such as hypotension, altered mental status, cyanosis, or pulmonary edema. Sudden cardiac death is rare but can occur (approximately 1 per 1,000 patient-years).


Diagnosis is based primarily on ECG findings. During sinus rhythm, the classic triad includes short PR interval, delta wave, and widened QRS complex. During tachyarrhythmias, ECG patterns vary depending on the mechanism: orthodromic AVRT typically produces a narrow complex tachycardia (150–250 bpm), while antidromic AVRT produces a wide complex tachycardia. Atrial fibrillation in WPW appears as an irregular wide complex rhythm with variable QRS morphology, which is a dangerous presentation.


Management depends on patient stability and rhythm type. Unstable patients (hypotension, chest pain, altered mental status) require immediate synchronized cardioversion, starting at 100 J and escalating as needed. In stable patients, initial management includes vagal maneuvers such as the Valsalva maneuver or carotid sinus massage (if no contraindications).


For narrow complex tachycardia (orthodromic AVRT), pharmacologic therapy includes Adenosine (6 mg rapid IV bolus, followed by 12 mg if needed; pediatric: 0.1–0.2 mg/kg) or calcium channel blockers when the diagnosis is certain. For wide complex tachycardia or suspected WPW with atrial fibrillation, Amiodarone (150 mg IV over 10 minutes, followed by infusion) or Procainamide (6–13 mg/kg IV infusion) are preferred.


Critically important: AV nodal–blocking agents such as β-blockers, calcium channel blockers, digoxin, and lidocaine must be avoided in patients with WPW and wide complex tachycardia or atrial fibrillation, as they may enhance conduction through the accessory pathway and precipitate fatal ventricular arrhythmias.


Disposition depends on clinical presentation. Patients with instability, syncope, or refractory arrhythmias require admission and monitoring. Most stable patients who convert to sinus rhythm can be discharged with cardiology follow-up, including consideration of electrophysiologic studies and radiofrequency ablation, which offers definitive treatment.


Key clinical pearls include maintaining a high suspicion for WPW in any tachydysrhythmia, avoiding AV nodal blockers in uncertain wide complex rhythms, and addressing anticoagulation if arrhythmia duration exceeds 48 hours due to embolic risk.

Emergency and Acute Medicine – Drug Withdrawal




Drug Withdrawal refers to the constellation of symptoms that occur when a substance that has been used chronically is abruptly reduced or discontinued. The hallmark of many withdrawal syndromes—particularly those involving benzodiazepines, barbiturates, and opioids—is neuroexcitation, resulting from adaptive changes in the central nervous system. While withdrawal from sedative-hypnotics such as benzodiazepines and barbiturates can be life-threatening, opioid withdrawal is typically not fatal but can be extremely uncomfortable. Withdrawal from stimulants such as cocaine and amphetamines is also generally not life-threatening but can cause significant psychological distress.


The pathophysiology involves neuroadaptation to chronic drug exposure. With prolonged use, the body adjusts to the presence of the substance, leading to tolerance, where increasing doses are needed to achieve the same effect. When the drug is removed, these adaptations persist, resulting in withdrawal symptoms. It is important to distinguish tolerance from withdrawal, as they are related but separate phenomena.


Clinical features vary depending on the substance. Benzodiazepine and barbiturate withdrawal presents with anxiety, agitation, tremor, insomnia, tachycardia, hypertension, hyperthermia, and autonomic instability, with the potential for seizures and life-threatening complications. Opioid withdrawal is characterized by restlessness, irritability, drug craving, yawning, piloerection (“goosebumps”), mydriasis, nausea, vomiting, diarrhea, abdominal pain, tachycardia, and hypertension. Cocaine withdrawal typically manifests with depressed mood, fatigue, vivid dreams, sleep disturbances, and psychomotor changes, while amphetamine withdrawal presents with fatigue, irritability, anxiety, and sleep disturbances.


Diagnosis is primarily clinical and relies on a detailed substance use history, including the type of drug, time of last use, and any previous withdrawal episodes. Physical examination focuses on vital signs and signs of autonomic instability. Laboratory testing (electrolytes, renal function, glucose, CBC) may be helpful to identify complications or alternative diagnoses, although urine drug screening rarely changes acute management. Imaging is reserved for cases where the diagnosis is unclear or other pathology is suspected.


Management begins with initial stabilization, including airway, breathing, and circulation, IV access, fluid resuscitation, and monitoring. Treatment is then tailored to the specific withdrawal syndrome. For benzodiazepine or barbiturate withdrawal, aggressive supportive care and substitution with a long-acting agent of the same class are recommended, using medications such as Diazepam (5–10 mg IV repeated as needed; 5–20 mg PO for mild symptoms) or Lorazepam (1–2 mg PO or 2 mg IV repeated as needed). Severe cases or seizures may require Phenobarbital (15–20 mg/kg IV).


In opioid withdrawal, treatment is largely supportive. Symptom control includes antiemetics such as Ondansetron (4–8 mg PO/IV) and autonomic symptom relief with Clonidine (0.1–0.3 mg PO every 4–6 hours). Opioid replacement therapy may be considered in certain cases, especially when withdrawal complicates other medical conditions. For cocaine and amphetamine withdrawal, management is supportive, focusing on rest, hydration, and monitoring for psychiatric symptoms.


Disposition depends on severity and associated risks. Patients with moderate-to-severe symptoms, persistent withdrawal, psychosis, autonomic instability, or significant comorbid conditions require admission. Those with mild symptoms who respond to therapy and are psychiatrically stable may be discharged with appropriate follow-up. Referral to a detoxification or rehabilitation program is essential for long-term management.


A key clinical pearl is to avoid misdiagnosing other serious medical conditions as withdrawal, as infections, metabolic disturbances, or intracranial pathology may mimic withdrawal syndromes. Additionally, clinicians should ensure adequate dosing of benzodiazepines in sedative withdrawal, as under-treatment can lead to severe complications, including seizures.

​

Emergency and Acute Medicine – Alcohol Withdrawal




Alcohol Withdrawal is the most common withdrawal syndrome encountered in the emergency department and represents a spectrum of neuroexcitatory symptoms that occur after cessation or reduction of chronic alcohol use. The underlying mechanism involves neuroadaptation: chronic alcohol exposure enhances inhibitory GABA activity and suppresses excitatory NMDA receptors. When alcohol intake stops, this balance shifts toward excess excitation, leading to autonomic hyperactivity and neurologic symptoms. Repeated withdrawal episodes may worsen severity through a process known as kindling, increasing the risk of life-threatening complications.


Alcohol withdrawal progresses through a predictable timeline with four major clinical stages. Early withdrawal begins within 6–8 hours after the last drink and lasts 1–2 days, presenting with tremulousness, anxiety, palpitations, nausea, and anorexia. Withdrawal seizures typically occur between 6–48 hours and are usually brief, generalized seizures. Alcoholic hallucinosis develops within 12–48 hours and is characterized by visual (most common), tactile, or auditory hallucinations, often with a relatively clear sensorium. The most severe form, delirium tremens (DTs), occurs 48–96 hours after cessation and may last up to 5 days, presenting with tachycardia, hypertension, diaphoresis, agitation, and delirium. DTs occur in approximately 5% of patients but carry a high mortality rate of 5–15%.


Diagnosis is primarily clinical, based on history and physical examination. Key historical features include the time of last alcohol intake, history of prior withdrawal episodes, and severity of previous symptoms. Physical examination should focus on vital signs and signs of autonomic instability. Laboratory evaluation typically includes electrolytes, renal function, glucose, magnesium, CBC, and blood alcohol level, as well as screening for coexisting conditions such as infection. Imaging such as CT of the head is reserved for patients with altered mental status or unclear diagnosis.


Management begins with initial stabilization, including airway, breathing, and circulation, IV access, fluid resuscitation, and continuous monitoring. The cornerstone of treatment is benzodiazepines, which act by enhancing GABA activity and reducing CNS hyperexcitability. Commonly used agents include Diazepam (5–10 mg IV, repeat as needed; 5–20 mg PO for mild symptoms) and Lorazepam (2 mg IV or PO every 2–4 hours as needed). High or repeated dosing is often required to adequately control symptoms.


In severe or refractory cases, adjunctive therapies such as Phenobarbital (15–20 mg/kg IV for severe symptoms or status epilepticus) or Propofol (25–75 μg/kg/min infusion) may be used, particularly in ICU settings. Supportive care includes correction of electrolyte abnormalities and monitoring for complications such as arrhythmias or aspiration.


Disposition depends on severity. Patients with moderate-to-severe withdrawal, persistent symptoms, delirium tremens, or significant comorbidities require hospital admission, often to a monitored or intensive care setting. Patients with mild symptoms that respond well to therapy may be discharged with close follow-up and referral to a detoxification program.


A key clinical pearl is to avoid under-treatment with benzodiazepines, as inadequate dosing can lead to progression to severe withdrawal or DTs. Additionally, clinicians must remain vigilant for alternative diagnoses, as medical conditions such as infection, hypoglycemia, or intracranial pathology may mimic or coexist with alcohol withdrawal.

​

Emergency and Acute Medicine – Wheezing




Wheezing is a high-pitched, musical sound produced by turbulent airflow through narrowed airways, typically with a dominant frequency around 400 Hz. It occurs when airflow causes vibration of bronchial walls, similar to a reed instrument. Wheezing is most prominent when airway diameters are between 2–5 mm; larger airways produce lower-pitched sounds, while very small airways (<2 mm) may not transmit sound effectively due to energy loss. Airway narrowing may result from bronchoconstriction, inflammation, edema, or obstruction, and identifying the underlying mechanism is critical in acute care settings.


The causes of wheezing are broad and include both small-airway (pulmonary) and large-airway etiologies. Small-airway causes commonly include Asthma, Chronic Obstructive Pulmonary Disease, pulmonary edema, anaphylaxis, and aspiration. Certain drugs such as ACE inhibitors, β-blockers, aspirin, and NSAIDs may precipitate bronchospasm or allergic reactions. Less common causes include pulmonary embolism, carcinoid tumors, and occupational lung diseases like byssinosis. Large-airway causes include foreign body aspiration, vocal cord dysfunction, epiglottitis, tumors, and smoke inhalation. In pediatric populations, common causes include Bronchiolitis, asthma, croup, and congenital airway abnormalities such as tracheomalacia.


Clinically, wheezing presents as a whistling sound during breathing, often accompanied by dyspnea, cough, chest tightness, and respiratory distress. Diffuse wheezing suggests generalized airway disease such as asthma or pulmonary edema, while focal wheezing raises concern for localized obstruction such as pneumonia or foreign body. Associated findings may include tachypnea, tachycardia, cyanosis, and use of accessory muscles. A critical aspect of assessment is the patient’s mental status—fatigue, confusion, or lethargy may indicate impending respiratory failure and necessitate urgent airway management.


Evaluation begins with assessment of severity and oxygenation. Pulse oximetry is essential for monitoring oxygen saturation, while peak expiratory flow (PEF) helps quantify airway obstruction and response to treatment. Chest X-ray may be used to evaluate for pneumonia, pulmonary edema, or foreign body. Arterial blood gas (ABG) may be useful in severe cases to assess for rising CO₂ and acidosis, indicating respiratory fatigue. Additional investigations such as ECG or laryngoscopy may be indicated depending on suspected etiology.


Management focuses on rapid stabilization and reversal of airway obstruction. Initial treatment includes supplemental oxygen and airway support. Bronchodilators are first-line therapy, particularly Albuterol given as 2.5–5 mg nebulized every 20 minutes for 3 doses (pediatric: 0.15 mg/kg per dose, minimum 2.5 mg). Systemic corticosteroids such as Prednisone (40–80 mg PO; pediatric 1 mg/kg/day, max 60 mg) or Methylprednisolone (40–80 mg IV) are used to reduce airway inflammation and prevent relapse.


For moderate to severe cases, Ipratropium Bromide (0.5 mg nebulized every 20 minutes for 3 doses) can be added to β-agonist therapy. Additional therapies include magnesium sulfate (0.1 mL/kg of 50% solution IV over 20 minutes) in severe asthma, terbutaline (0.25 mg SC), and heliox in selected cases. In pediatric croup, racemic epinephrine (0.25–0.5 mL nebulized) may be used. Intubation is indicated for patients with impending respiratory failure, and Ketamine may be preferred due to its bronchodilatory properties.


Disposition depends on clinical response. Patients with persistent hypoxia, worsening symptoms, or underlying serious conditions require admission. Those who improve with treatment, achieve PEF >70% predicted, and maintain adequate oxygenation may be discharged with follow-up and clear return precautions. Patients with asthma should receive an action plan and appropriate outpatient referral.


A key clinical pearl is to always consider non-asthma causes of wheezing, especially in cases of focal findings or poor response to bronchodilators. Additionally, clinicians must be prepared for rapid airway deterioration, particularly when administering sedatives or managing severe respiratory distress.

​

Emergency and Acute Medicine – West Nile Virus




West Nile Virus is a mosquito-borne viral illness caused by an RNA virus from the Flaviviridae family. It is transmitted primarily by infected Culex mosquito during late summer and early fall. Wild birds serve as the main reservoir, and humans become incidental hosts through mosquito bites. Less commonly, transmission can occur via blood transfusion, organ transplantation, or occupational exposure. Since its introduction to the Western Hemisphere in 1999, the virus has become endemic in many regions. After recovery, immunity is generally lifelong, and recurrence is rare.


The clinical presentation of West Nile virus infection varies widely. Approximately 80% of infected individuals are asymptomatic, while about 20% develop a mild, self-limited febrile illness resembling a viral syndrome. A small proportion—roughly 1 in 150 patients—develops neuroinvasive disease, such as meningitis or encephalitis. The incubation period is typically 2–6 days but may extend up to 2–3 weeks, especially in immunocompromised individuals. Severe disease carries a mortality rate of around 7%, with higher risk in elderly patients and those with weakened immune systems.


Patients with mild disease usually present with fever, malaise, headache, anorexia, and sometimes gastrointestinal symptoms such as nausea or diarrhea. These symptoms typically resolve within a week, although fatigue and weakness may persist for several weeks. In more severe cases, neurologic involvement dominates the clinical picture. Patients may develop altered mental status, confusion, seizures, or focal neurologic deficits. A characteristic feature is profound muscle weakness or flaccid paralysis, which can resemble poliomyelitis due to involvement of anterior horn cells. Cranial nerve abnormalities, bulbar dysfunction, and movement disorders may also occur. A transient maculopapular rash may appear on the trunk and extremities.


Diagnosis relies primarily on serologic testing, with the most sensitive method being detection of IgM antibodies using MAC-ELISA in serum or cerebrospinal fluid (CSF). IgM antibodies are usually detectable within the first week of illness and may persist for months. CSF analysis in neuroinvasive disease typically shows lymphocytic pleocytosis, elevated protein, and normal glucose. Imaging such as CT is often normal, while MRI may reveal nonspecific signs of central nervous system inflammation.


Management of West Nile virus is primarily supportive, as there is currently no specific antiviral therapy or vaccine available. Initial stabilization includes airway, breathing, and circulation support, along with seizure precautions if indicated. Treatment consists of intravenous fluids for dehydration, antipyretics for fever, and analgesics for pain. In patients presenting with suspected meningitis or encephalitis, empiric antibiotics and Acyclovir may be initiated until other treatable causes, particularly herpes simplex virus infection, are excluded. No medications—including interferon, ribavirin, or corticosteroids—have proven benefit in controlled studies.


Disposition depends on disease severity. Patients with neurologic involvement, dehydration, advanced age, or immunocompromise require hospital admission, often with neurologic monitoring. Those with mild illness who can tolerate oral intake and have no signs of central nervous system involvement may be discharged with close follow-up. Long-term sequelae such as fatigue, memory impairment, weakness, and headache may persist for weeks to months, and follow-up with a neurologist is often recommended in severe cases.


A key clinical pearl is to always consider other causes of encephalitis, particularly herpes simplex virus, since it is treatable and requires early intervention.

​

Emergency and Acute Medicine: Warts




Warts are benign proliferative lesions of the skin and mucous membranes caused by infection with the Human papillomavirus. The virus infects the basal layer of epithelial tissue, leading to cellular proliferation and increased vascularity, which gives rise to the characteristic verrucous, hyperkeratotic appearance. Warts are extremely common, particularly in children and adolescents, and most resolve spontaneously due to a cell-mediated immune response—about one-third within 6 months, two-thirds within 2 years, and up to 90% within 5 years.


There are several clinical types of warts depending on location and HPV subtype. Verruca vulgaris (common warts) typically occur on the dorsum of the hands, fingers, and around nails and are usually asymptomatic. Verrucae plantaris (plantar warts) occur on weight-bearing areas of the feet such as the heels and metatarsal heads and are often painful due to pressure. Flat (juvenile) warts appear as small, smooth, flesh-colored lesions on sun-exposed areas such as the face, neck, and extremities and may spread with shaving. Anogenital warts, also known as condyloma acuminata, are sexually transmitted and commonly caused by HPV types 6 and 11, while types 16 and 18 are associated with cervical cancer. These lesions are often soft, multiple, and have a cauliflower-like appearance.


Transmission of HPV occurs through direct skin-to-skin contact, indirect contact via contaminated surfaces, or autoinoculation, especially in children who scratch or bite affected areas. The incubation period is variable, ranging from weeks to over a year. In pediatric cases, warts are common, but the presence of anogenital warts should raise concern for possible sexual abuse, particularly in younger children.


Diagnosis is primarily clinical, based on the characteristic appearance of lesions. Common and plantar warts disrupt normal skin lines and may show pinpoint bleeding when scraped. Flat warts are smooth and subtle, while anogenital warts are soft and pedunculated. Laboratory testing is generally unnecessary, although application of acetic acid can help highlight lesions by causing whitening. Biopsy is reserved for atypical, persistent, or suspicious lesions, especially in immunocompromised patients.


Management depends on the type, location, and patient preference. Many warts require no treatment, especially in children, due to high rates of spontaneous resolution. For cutaneous warts, first-line therapy includes topical salicylic acid, typically 17% over-the-counter or up to 70% prescription strength, applied after soaking the wart for 10–20 minutes, left on overnight, and followed by gentle debridement. Treatment is repeated regularly and may take weeks to months. Another simple method is duct tape occlusion therapy, which may be particularly useful in children.


For anogenital warts, treatment options include patient-applied therapies such as Imiquimod (5% cream applied three times per week for up to 16 weeks) and Podofilox (0.5% solution or gel applied twice daily for 3 days followed by 4 days off, repeated up to 4 cycles). Provider-administered treatments include podophyllin (10–25% weekly application), trichloroacetic acid (80–90% weekly for 6–10 weeks), and cryotherapy with liquid nitrogen every 1–2 weeks. These treatments require caution, especially in pregnancy or when applied to sensitive mucosal areas.


Preventive strategies include vaccination with Gardasil, which protects against HPV types 6, 11, 16, and 18 and is given as a 3-dose series over 6 months. This vaccine significantly reduces the risk of genital warts and HPV-related cancers. Another vaccine, Cervarix, targets oncogenic strains associated with cervical cancer.


Most patients can be managed as outpatients, but referral to dermatology or gynecology is appropriate for treatment-resistant cases, atypical lesions, or anogenital involvement. Follow-up is important to ensure treatment response and monitor for recurrence. Patients should be advised to return if lesions change, become painful, or fail to improve.


A key clinical pearl is that HPV vaccines do not protect against all HPV types, and patients may still develop warts despite vaccination. Additionally, clinicians should always consider the broader clinical context, including the possibility of immunosuppression or, in pediatric cases with anogenital lesions, safeguarding concerns.

​

Emergency and Acute Medicine: Warfarin Complications




Warfarin is a widely used oral anticoagulant that works by inhibiting vitamin K–dependent clotting factors (II, VII, IX, and X), thereby affecting both the extrinsic and common coagulation pathways. It is commonly prescribed for conditions such as venous thromboembolism, atrial fibrillation, and prosthetic heart valves. Its therapeutic effect is monitored using the International Normalized Ratio, with typical target ranges of 2–3 or 2.5–3.5 depending on indication. However, due to its narrow therapeutic window and numerous interactions, warfarin is associated with significant complications, most notably bleeding.


Bleeding is the most common complication, occurring in up to 15% of patients annually, with major bleeding events in about 5% and fatal bleeding (most often Intracranial hemorrhage) in less than 1%. The risk of bleeding increases significantly when the INR exceeds 4. Patients may present with a wide spectrum of symptoms, ranging from occult bleeding to life-threatening hemorrhage involving the gastrointestinal tract, central nervous system, or retroperitoneum. Conversely, subtherapeutic INR levels may result in breakthrough thrombosis, particularly in high-risk patients.


Several factors predispose patients to unstable INR levels and complications, including advanced age (>75 years), comorbidities such as hypertension, diabetes, renal or liver disease, malignancy, and hyperthyroidism. Drug and dietary interactions are especially important: antibiotics, Amiodarone, NSAIDs, and certain herbal supplements (e.g., ginkgo, garlic) can increase INR, while drugs like Rifampin, carbamazepine, and high vitamin K intake can decrease it. Warfarin is contraindicated in pregnancy due to its teratogenic effects.


A unique complication is warfarin-induced skin necrosis, which typically occurs within the first week of therapy and is associated with protein C deficiency. It presents as painful skin lesions that progress to necrosis with central eschar formation. Limb gangrene may also occur due to venous thrombosis. In cases of overdose or ingestion of long-acting anticoagulants (e.g., “superwarfarins” found in rodenticides), patients may initially be asymptomatic but develop prolonged coagulopathy requiring extended monitoring.


Evaluation requires a thorough history, including indication for anticoagulation, recent dose changes, medication interactions, and prior INR values. Physical examination should focus on signs of bleeding (e.g., ecchymosis, pallor, hypotension) and subtle neurologic changes suggestive of intracranial bleeding. Laboratory testing includes PT/INR, CBC, renal and liver function tests, and type and crossmatch if bleeding is suspected. Imaging, particularly CT scans, should be obtained liberally to detect occult bleeding, especially in trauma patients or those with neurologic symptoms.


Management depends on the INR level and presence of bleeding. For patients with INR <5 and no bleeding, the next dose may be held or reduced with close monitoring. For INR 5–9 without bleeding, holding warfarin and administering Vitamin K1 at 1–5 mg PO may be appropriate, especially in high-risk patients. For INR ≥9 without bleeding, vitamin K 2.5–5 mg PO is recommended. In cases of serious or life-threatening bleeding (any INR), immediate reversal is required with vitamin K 10 mg IV (slow infusion over 10–30 minutes) along with clotting factor replacement.


Rapid reversal is best achieved using Prothrombin complex concentrate, which contains clotting factors II, VII, IX, and X. Dosing is weight- and INR-dependent: 25 U/kg for INR 2–3.9, 35 U/kg for INR 4–5.9, and 50 U/kg for INR ≥6. PCC is preferred in cases of intracranial hemorrhage, massive bleeding, or when volume overload is a concern. Alternatively, Fresh frozen plasma may be used, typically 3–4 units (≈1 L), though it carries risks such as fluid overload and slower INR correction. In refractory or complex cases, adjuncts such as factor VIIa may be considered.


Disposition depends on severity. Patients with active bleeding, especially involving the CNS, GI tract, or retroperitoneum, require admission and often ICU-level care. Stable patients with asymptomatic supratherapeutic INR and reliable follow-up may be discharged with close monitoring. Follow-up within 24–48 hours for repeat INR testing is essential.


A key clinical pearl is to maintain a low threshold for imaging in anticoagulated patients, even after minor trauma, as serious bleeding may occur without obvious symptoms. Additionally, vitamin K should generally not be given for INR <5 without bleeding, and IV vitamin K should be reserved for severe cases due to the rare but serious risk of anaphylaxis.

​